Succinate-semialdehyde dehydrogenase (NAD(P) ) (EC 1.2.1.24), often abbreviated as SSADH, is an enzyme that catalyzes the irreversible oxidative deamination of succinate semialdehyde to succinate. This reaction is a crucial step in the catabolism of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system.
Reaction: The enzyme catalyzes the following chemical reaction: Succinate semialdehyde + NAD(P)$^{+}$ + H$_{2}$O $\rightleftharpoons$ Succinate + NAD(P)H + H$^{+}$
The enzyme can utilize either nicotinamide adenine dinucleotide (NAD$^{+}$) or nicotinamide adenine dinucleotide phosphate (NADP$^{+}$) as a cofactor, reducing them to NADH or NADPH, respectively.
Metabolic Pathway: SSADH is a key enzyme in the GABA shunt, an alternative pathway to the typical tricarboxylic acid (TCA) cycle for GABA degradation. In this pathway, GABA is first transaminated to succinate semialdehyde by GABA transaminase. Subsequently, SSADH converts succinate semialdehyde to succinate, which can then re-enter the TCA cycle.
Biological Significance and Clinical Relevance: SSADH plays a critical role in maintaining the balance of GABA and related metabolites in the brain. Deficiency in this enzyme, known as Succinic Semialdehyde Dehydrogenase Deficiency (SSADH deficiency) or 4-hydroxybutyric aciduria, is a rare autosomal recessive disorder. This deficiency leads to the accumulation of succinate semialdehyde and its reduced product, gamma-hydroxybutyrate (GHB), in the brain and bodily fluids. Patients with SSADH deficiency typically present with a spectrum of neurological symptoms, including developmental delay, intellectual disability, hypotonia, ataxia, seizures, and behavioral problems. The accumulation of these metabolites is thought to be neurotoxic and underlies the clinical manifestations of the disorder.